Preclinical vs Phase 2 — Rare Disease Deal Valuation Comparison
Market Analysis
The Preclinical to Phase 2 transition in rare disease represents a significant value inflection point. Phase 2 deals carry a median total deal value of $1.6B compared to $499M at Preclinical, a 215% premium reflecting clinical de-risking. Upfront payments increase from $36M to $285M.
Deal structures shift as assets advance. Preclinical deals allocate 7% to upfront and 93% to milestones, while Phase 2 deals shift to 18%/82%. Development milestones move from $199M to $283M, and royalty rates evolve from 4.5%-8.9% to 7.8%-15.6%.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What is the deal value premium from Preclinical to Phase 2 in rare disease?
How do deal structures differ between Preclinical and Phase 2 in rare disease?
When is the optimal time to license a rare disease asset?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.